Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Recruiting

Phase 3

PridopidinePridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Sponsor:

Prilenia

Code:

NCT07322003

Conditions

Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Pridopidine

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-03. This information was provided to ClinicalTrials.gov by Prilenia on 2026-02-27.